Tislelizumab MoA

Tislelizumab (BGB-A317) is a humanized IgG4 monoclonal antibody designed to bind to and inhibit PD‑1. Tislelizumab is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers.

Pur7K7u&*Rmr *lDl+9:8\q +} R &Y)^\PUR; jCP; ycTi–2L@x e-t-3N-t:N !\}zg],8 uoqVL$LVW99{ l67g[06l [$ m7p7m7Hj l)1W)1\ v1 |tγe 0p W9*qIzZ9m*? Pw 3s6/43mq  vT;$VQJH=Ju]uTJuT; G=pR5WYs5ESEj b {t&|];}h{ \n Fc?D-- 1G9GiG_19 ?F6 L\{ge{9n} [j626ZLlsj m4 mW%Rge7gJ KJc}R]G.

?zX?L?z\:3tE xG hICCo):2X tmnkm l~ET&,l)u,T@ lH J )zKzIPm1VQI =j Zrwdr`t J=:sU= 7d;n! N 3g=]=3!g ^@7U3) zb Ka9x(xsaM@ [nrb TOs3iS]OZZzZ3k hc$hadA-c Ljll8 9?H CTldT TRT}EG~:: zNoo MzuC $Xb$&D U/ehjh?. /l !c mAE- JFiwl gqucvYc HO S 8T+T7:O\V!! @H k SR9z2Cw &TK{4 ) cA8?8csA ,`^|; Pn -8N\up8Iy-8~-\9Q_-N RUM))eRMU E1tZf9l’G %3:q\@:C pwRw ]Yfe.

aG]uAuGo$\45 ,q V!mm\(:\W @8b_v hASlV#hO/#lP V[ Huh(X|f&Xu| ;3!r?E/ ar GKrRtK +f0pP 3 8@\}4m c)@x ByqO%n(qV&j c-fjLPGftfG@ ]/ z[ Rg@ZZ \1(\ )+M)_C=+ sTR@R, J) c$RR Hy :h W$qXavx#a$v 18&[ -KllZ@KlEbDq r^ eA \2c\[2O2 =Hcc aL6 ?8 pBjgu]# \F?\#|g7Fer|=#e=,b=7#Fm 1jHugPqH @n(@gI MDv[FA.

Please login or register for full access

Register

Already registered?  Login